Replies to post #1948 on Galectin Therapeutics Inc. (GALT)

[Tesla1]

Darwinian: From what I have read, GCS-100 and GR-MD-02 could not be more different than each other. Opinion, I believe the issue could be that La Jolla was looking to move LJ-1010 from preclinical to Phase 1 (human) Studies. Their timeline seemed pretty quick to me from discovery to preclinical to Phase 1. The process normally requires many years to complete and they were making this happen within a mere matter of months. They probably would have had to spend a few more years in preclinical development for LJ-1010 and they just have other priorities right now with the compounds that they have recently acquired, one of which has an approved SPA for a phase 3 clinical trial. My opinion is that La Jolla at least appeared to be transitioning from GCS-100 to LJ-1010 and it could have ended up requiring several more years to make that happen. I could be wrong but that is my two cents on the subject.